Loading data
AMBONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.47 m USD | 9.39 m USD | 9.16 m USD | 14.84 m USD | 17.82 m USD |
| Cost of revenue | 4.28 m USD | 4.41 m USD | 6.67 m USD | 14.56 m USD | 15.39 m USD |
| Gross profit | 5.19 m USD | 4.99 m USD | 2.49 m USD | 284 k USD | 2.42 m USD |
| Research and development expense | 628 k USD | 438 k USD | 484 k USD | — | — |
| Operating profit | 112 k USD | -722 k USD | -4.31 m USD | -9.49 m USD | -8.63 m USD |
| Profit before tax | 1.37 m USD | -530 k USD | -3.16 m USD | -9.25 m USD | -7.19 m USD |
| Income tax expense | 6 k USD | -839 k USD | 14 k USD | — | -505 k USD |
| Net income (reported basis) | 1.36 m USD | 309 k USD | -3.18 m USD | -14.31 m USD | 313 k USD |
| Net income attributable to common shareholders | 1.36 m USD | 309 k USD | -3.18 m USD | -14.07 m USD | 470 k USD |
| Basic earnings per share | 0.02 USD/share | 0.01 USD/share | -0.06 USD/share | -0.19 USD/share | -0.14 USD/share |
| Diluted earnings per share | 0.02 USD/share | 0.01 USD/share | -0.06 USD/share | -0.19 USD/share | -0.14 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.